Scarica l'app Stockscreener
763.00
5.02%
36.49
Dopo l'orario di chiusura:
757.00
-6.00
-0.79%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$726.51
Aprire:
$726.96
Volume 24 ore:
6.22M
Relative Volume:
1.42
Capitalizzazione di mercato:
$722.15B
Reddito:
$53.26B
Utile/perdita netta:
$13.80B
Rapporto P/E:
49.87
EPS:
15.3
Flusso di cassa netto:
$-50.20M
1 W Prestazione:
+2.14%
1M Prestazione:
+4.15%
6M Prestazione:
-7.62%
1 anno Prestazione:
-13.88%
Intervallo 1D:
$725.31
$766.35
Intervallo di 1 settimana:
$712.05
$766.35
Portata 52W:
$623.78
$937.00
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
763.00 | 651.28B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
185.42 | 437.40B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
231.54 | 394.23B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
128.24 | 240.24B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
83.93 | 196.28B | 63.43B | 16.42B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly and Pasadena-Based Alexandria Launch New Biotech Hub in San Diego’s Torrey Pines Alexandria Real Estate Equities, Inc., headquartered in downtown Pasadena, has partnered with Eli Lilly and Company to open a new Lilly Gateway Labs facility a - facebook.com
Stock Market Today: Pfizer Rallies on Trump Drug Pricing Deal and U.S. Investment Pledge - The Motley Fool
Eli Lilly and Company (LLY) Opens a New Lilly Gateway Labs Innovation Hub in San Diego - Yahoo Finance
Eli Lilly in discussions with White House for TrumpRx dealreport - Seeking Alpha
Why Are Eli Lilly (LLY) Shares Soaring Today - TradingView
Eli Lilly tells Bloomberg in ‘active discussions’ with administration on prices - TipRanks
Trump, Pfizer announce MFN deal; Lilly, others to come - pharmaphorum
Eli Lilly and Pasadena-Based Alexandria Launch New Biotech Hub in San Diego’s Torrey Pines - Pasadena Now
Trump’s MFN deadline came and went - statnews.com
Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma - Stocktwits
Lilly’s head scientist discusses its GLP-1 pill, Alzheimer’s strategy, and finding promising ideas and startups - statnews.com
How Eli Lilly And Company (LLY) Affects Rotational Strategy Timing - news.stocktradersdaily.com
News | Houston developer says landing major Eli Lilly campus enables his late father's legacy to live on - CoStar
Trump announced a 100% tariff on pharmaceuticals. Eli Lilly is likely exempt - WFYI
Alexandria & Lilly Unite at San Diego's One Alexandria Square - Yahoo
Trump places 100% tariff on drugs. What this means for Eli Lilly - IndyStar
Weight Loss Wars: Is Novo Nordisk’s Dominance Safe Against Eli Lilly? - Barchart.com
How Eli Lilly (LLY) Balances Dividend Payouts With Long-Term Innovation - Yahoo Finance
Eli Lilly: Strong Buy On Sustained Growth, Expanding Moat, And Pipeline Depth (NYSE:LLY) - Seeking Alpha
This Is What Whales Are Betting On Eli Lilly - Benzinga
Virginia Wins $5B Eli Lilly Biomanufacturing Facility - Engineering News-Record
Eli Lilly: Is LLY Stock Set For A 20% Breakout? - Forbes
Eli Lilly Opens San Diego Facility - CommercialSearch
Guggenheim reiterates Buy rating on Eli Lilly stock, maintains $875 target - Investing.com India
Eli Lilly and Company (LLY) Plans $6.5B Investment to Bolster Pipeline Production - Yahoo Finance
Is Eli Lilly and Company (LLY) the Best Pharma Stock to Buy for Long Term Growth? - MSN
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring? - MSN
West Branch Capital LLC Has $6.42 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Positive Report for Eli Lilly & Co (LLY) from CFRA - The Globe and Mail
Precision Trading with Eli Lilly And Company (LLY) Risk Zones - news.stocktradersdaily.com
Did European and U.S. Drug Approvals Plus Texas Expansion Just Shift Eli Lilly’s (LLY) Investment Narrative? - simplywall.st
How Investors May Respond To Alexandria Real Estate Equities (ARE) Expanding Biotech Innovation Hubs With Eli Lilly - simplywall.st
Nvidia, Broadcom, CrowdStrike, Eli Lilly, SoundHound: Insider Sales Shake Market - TipRanks
Eli Lilly and Company $LLY Shares Sold by State of Alaska Department of Revenue - MarketBeat
True North Advisors LLC Has $2.30 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (LLY) Announces New Innovation Hub as President Trump Threatens Pharma Tariffs - TipRanks
Eli Lilly terminates trial of Zepbound and muscle-sparing combo - Clinical Trials Arena
Eli Lilly and Company (NYSE:LLY) Shares Up 1.4%Here's What Happened - MarketBeat
Alexandria, Eli Lilly Open Torrey Pines Innovation Hub - Connect CRE
Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why. - Barron's
Why Lilly chose Houston for $6.5B plant - KHOU
Eli Lilly upgraded at CFRA as minimal impact seen from pharma tariffs - Seeking Alpha
Eli Lilly, Intel, Paccar, GlobalFoundries, Boeing, AppLovin, Costco, Electronic Arts, and More Movers - Barron's
ELI LILLY AND COMPANY (LLY) - MSN
Eli Lilly, Amgen tout U.S. investments as Trump imposes 100% pharma tariffs - MSN
Eli Lilly’s New Study on LY3537031: A Potential Game-Changer for Renal Impairment Treatment? - TipRanks
FDA Approves Eli Lilly's Drug For Advanced Breast Cancer - AOL.com
Global drugmakers rush to boost US presence as tariff threat looms - Reuters
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.09%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):